Lilly shared detailed new weight-loss data for its amylin-incretin combination eloraTZP, reporting up to 23.3% mean weight loss in adults with obesity and type 2 diabetes in updated conference communications. The result strengthens the case that the regimen is achieving substantial reductions in excess body weight within clinical study timeframes. The broader obesity pipeline context includes continued benchmarking against triple agonists and earlier weight-loss franchise benchmarks. The data also help frame dose-response expectations and the potential differentiation of amylin-linked mechanisms for long-term metabolic benefit. As Roche and Zealand-related amylin programs continue to advance in parallel, the Lilly readouts add pressure for payers and regulators to evaluate not only weight loss magnitude but also cardiometabolic endpoints and durability.